We are live on ! Find out more
INBX icon

Inhibrx
INBX

92 hedge funds and large institutions have $151M invested in Inhibrx in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 36 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

351% more call options, than puts

Call options by funds: $993K | Put options by funds: $220K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.59% less ownership

Funds ownership: 77.11% → 74.52% (-2.6%)

9% less funds holding

Funds holding: 101 → 92 (-9)

12% less capital invested

Capital invested by funds: $172M → $151M (-$21M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

50% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 36

Holders
92
Holders Change
-9
Holders Change %
-8.91%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
8
Increased
18
Reduced
36
Closed
15
Calls
$993K
Puts
$220K
Net Calls
+$773K
Net Calls Change
-$87K

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$4.87M
2
PHS
PFM Health Sciences
California
+$4.12M
3
SI
Sofinnova Investments
California
+$2.32M
4
HighTower Advisors
HighTower Advisors
Illinois
+$1.22M
5
GLF
Groupe la Francaise
France
+$1.03M

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$8.93M
2
CP
Castalian Partners
Minnesota
-$2.95M
3
SC
Slotnik Capital
Texas
-$1.37M
4
Jane Street
Jane Street
New York
-$844K
5
Marshall Wace
Marshall Wace
United Kingdom
-$825K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWF
26
Alpha Wealth Funds
Utah
$541K -$533K -39,286 -50%
Fidelity Investments
27
Fidelity Investments
Massachusetts
$522K -$19.1K -1,409 -4%
Morgan Stanley
28
Morgan Stanley
New York
$516K -$38.2K -2,815 -7%
YCM
29
Yakira Capital Management
Connecticut
$506K – – –
M
30
Murchinson
Ontario, Canada
$473K – – –
Charles Schwab
31
Charles Schwab
California
$457K – – –
BC
32
Birchview Capital
Vermont
$449K – – –
BFM
33
Boothbay Fund Management
New York
$395K – – –
APCM
34
Arbiter Partners Capital Management
New York
$393K – – –
UBS Group
35
UBS Group
Switzerland
$384K +$132K +9,711 +55%
Russell Investments Group
36
Russell Investments Group
United Kingdom
$378K -$371K -27,315 -50%
Jane Street
37
Jane Street
New York
$368K -$844K -62,119 -70%
N
38
Nuveen
North Carolina
$350K – – –
MWA
39
Meridian Wealth Advisors
Texas
$350K – – –
EWM
40
Empirical Wealth Management
Washington
$316K – – –
JC
41
JBF Capital
Colorado
$293K – – –
Corient Private Wealth
42
Corient Private Wealth
Florida
$286K -$502 -37 -0.2%
Mariner
43
Mariner
Kansas
$261K +$253K +18,667 New
AllianceBernstein
44
AllianceBernstein
Tennessee
$251K – – –
RC
45
Rangeley Capital
Connecticut
$249K -$429K -31,591 -64%
Goldman Sachs
46
Goldman Sachs
New York
$240K -$547K -40,282 -70%
XT
47
XTX Topco
Cayman Islands
$237K +$230K +16,918 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$216K +$8.49K +625 +4%
Barclays
49
Barclays
United Kingdom
$186K -$75.5K -5,558 -29%
BCM
50
Bluefin Capital Management
New York
$160K +$155K +11,408 New
1
2
3 4 5

INBX Hedge Fund Activity: Q1 2025 in Review

92 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q1 2025, worth a combined $151M — down 12% from $172M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of INBX and 8 opened new positions — a net loss of 7 holders — while 36 trimmed existing stakes and 18 added.

The largest buyer was Woodline Partners, opening a new position worth an estimated $4.87M. The largest seller was Walleye Capital, exiting entirely with an estimated $8.93M sold.

  • 92 institutional investors held Inhibrx (INBX) as of Q1 2025, down from 101 in Q4 2024.
  • Funds reported $151M of Inhibrx stock for Q1 2025, down 12% quarter-over-quarter.
  • 8 funds opened new Inhibrx positions in Q1 2025 and 15 closed out, a net change of -7 holders.
  • The largest Inhibrx buyer in Q1 2025 was Woodline Partners, an estimated $4.87M added.
  • The largest Inhibrx seller in Q1 2025 was Walleye Capital, an estimated $8.93M sold.

Based on aggregated 13F filings for Q1 2025.